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EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
Abstract 
The European Food Safety Authority (EFSA) has asked the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) to update the guidance on the scientific requirements for health claims related to gut 
and immune function published in 2011. Since then, the NDA Panel has completed the evaluation of 
Article 13.1 claims except for claims put on hold by the European Commission, and has evaluated 
additional health claim applications submitted pursuant to Articles 13.5 and 14, which are in the area 
covered by this guidance. In addition, the NDA Panel has developed the general scientific guidance for 
stakeholders for health claims applications which addresses general issues that are common to all 
health claims. This guidance is intended to assist applicants in preparing applications for the 
authorisation of health claims related to the immune system, the gastrointestinal tract and defence 
against pathogenic microorganisms. Examples of claims evaluated favourably by the Panel will be 
used to provide guidance to applicants on the scientific requirements for the substantiation of health 
claims in specific areas, whereas examples of claims evaluated unfavourably by the Panel will be used 
to illustrate the shortcomings that prevented the substantiation of these claims. The general 
document represents the views of the NDA Panel based on the experience gained to date with the 
evaluation of health claims, and it may be further updated, as appropriate, in the light of experiences 
gained from the evaluation of additional health claim applications.  
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Summary 
The European Food Safety Authority (EFSA) has asked the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) to revise the guidance on the scientific requirements for health claims related to gut 
and immune function published in 2011.  
Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims put 
on hold by the European Commission) and has evaluated additional health claim applications 
submitted pursuant to Articles 13.5 and 14 which are in the area covered by this guidance. In 
addition, the NDA Panel has developed the general scientific guidance for stakeholders for health 
claims applications which addresses general issues that are common to all health claims.  
The guidance document has been structured to avoid overlapping with the general scientific guidance 
for stakeholders on health claim applications. This guidance is intended to assist applicants in 
preparing applications for the authorisation of health claims related to the immune system, the 
gastrointestinal tract and defence against pathogenic microorganisms. Examples of claims evaluated 
favourably by the Panel are used to provide guidance to applicants on the scientific requirements for 
the substantiation of health claims in specific areas, whereas examples of claims evaluated 
unfavourably by the Panel are used to illustrate the shortcomings that prevented the substantiation of 
these claims. 
The guidance does not intend to provide an exhaustive list of beneficial physiological effects and 
studies/outcome variables which could be acceptable, or address potential health relationships and 
related outcome measures which have not yet been considered by the Panel in the context of a 
particular application. 
This guidance supersedes the guidance on the scientific requirements for health claims related to gut 
and immune function published in 2011. 
The guidance has been subject to public consultations, first on a discussion paper (from 18 June to 10 
September 2014) and subsequently on an updated version of the guidance (from 9 February to 23 
March 2015). This guidance document represents the views of the NDA Panel based on the 
experience gained to date with the evaluation of health claims, and it may be updated in the future 
following the evaluation of additional health claim applications. 
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Background as provided by EFSA 
Regulation (EC) No 1924/20061 harmonises the provisions related to nutrition and health claims and 
establishes rules governing the Community authorisation of health claims made on foods. According to 
the Regulation, health claims should be only authorised for use in the Community after a scientific 
assessment of the highest possible standard to be carried out by the European Food Safety Authority 
(EFSA). 
Owing to the scientific and technical complexity of health claims, the EFSA Panel on Dietetic products, 
Nutrition and Allergies (NDA Panel) has placed considerable focus on developing scientific criteria for 
substantiation of health claims and has published guidance on scientific substantiation of health claims 
since 2007.2  
To date, over 570 scientific opinions related to health claims have been published and the Panel notes 
that additional health relationships and outcome measures for specific claimed effects have been 
considered in the context of specific applications.  
Based on experiences gained with the evaluation of health claims, and to further assist applicants in 
preparing and submitting their applications for the scientific evaluation of health claims, the NDA 
Panel considers it necessary to update existing guidance documents, and/or to develop new guidance 
documents, on the scientific requirements for the substantiation of health claims. 
The NDA Panel also emphasises the importance of engaging in consultation with experts/stakeholders 
in the process of updating existing guidance documents and/or developing new guidance documents.   
It is proposed to undertake this task in a stepwise manner, taking into account the experience gained 
and new scientific evidence available to the NDA Panel, including outcomes of public consultations 
with experts/stakeholders.  
Owing to a high demand from stakeholders and questions received from applicants requesting 
clarification related to gut and immune function claims, it is proposed to start updating the existing 
Guidance document on the scientific requirements for health claims related to gut and immune 
functions (EFSA NDA Panel, 2011e). 
Terms of Reference as provided by EFSA 
The NDA Panel is requested by EFSA to update the existing Guidance document on scientific 
requirements for health claims related to gut and immune function.  
In this context, as an initial step, the Panel is requested to issue a statement to be released for public 
consultation to gather views from experts/stakeholders in the field before proceeding with the 
updating of the guidance document. The statement shall point out the issues to be covered in the 
guidance document, propose recommendations for the updating of the guidance document, and 
propose a timetable for the release of draft and final guidance. 
As a second step, taking into account the experience gained and new scientific evidence available to 
the NDA Panel, including the outcome of the public consultation on the statement, the Panel is 
requested to update and draft the Guidance document to be released for public consultation before 
finalisation. 
Before the adoption of the guidance document by the NDA Panel, the draft guidance needs to be 
revised taking into account the comments received during the public consultation. 
A technical report on the outcome of the public consultation on the guidance document shall be 
published, in which comments received on the statement shall be included. 
                                                          
1  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
2  http://www.efsa.europa.eu/en/nda/ndaclaims.htm  
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Assessment 
1. Introduction 
The Guidance on the scientific requirements for health claims related to gut and immune function 
(EFSA NDA Panel, 2011e) published in April 2011, laid down recommendations on specific issues that 
need to be addressed in the applications submitted for the substantiation of health claims in this area 
and was based on the experience gained by the European Food Safety Authority (EFSA) Panel on 
Dietetic products, Nutrition and Allergies (NDA Panel) with the evaluation of health claims. Since then, 
the NDA Panel has evaluated additional health claims related to the immune system, the 
gastrointestinal (GI) tract and defence against pathogenic microorganisms.  
Among the 2,758 IDs evaluated by the NDA Panel under Article 13(1) (function claims), 421 IDs were 
in the area covered by this guidance. A total of 157 IDs were on GI functions, 41 IDs on the 
absorption/digestion of nutrients, 120 IDs on immune functions, 87 IDs on defence against 
pathogens, 15 IDs on inflammation and one ID referred to a beneficial change in response to 
allergens. Of these, the following claims were evaluated favourably by the Panel: 
 claims based on the essentiality of nutrients (for copper, folate, iron, selenium, zinc, and 
vitamins C, D, A, B12 and B6);  
 claims related to bowel function/normal defecation (for dried prunes, lactulose, wheat bran 
fibre, rye fibre, oat and barley grain fibre);  
 one claim on GI discomfort caused by lactose intake in lactose intolerant individuals (for foods 
with reduced lactose content);  
 one claim on the reduction of intestinal gas accumulation (for activated charcoal); 
 claims related to the absorption of micronutrients (for vitamins C, D, meat or fish, fats), to the 
digestion of food (for calcium, chloride) and to lactose digestion (for lactase and live yoghurt 
cultures).  
Among the 463 applications submitted to EFSA as of 29/07/2015 under Article 13(5) and Article 14, 
155 claims were relevant to this guidance (90 were withdrawn during the evaluation, 58 were 
evaluated/finalised by the NDA Panel and seven were under evaluation). Of these, the following 
claims were evaluated favourably by the Panel: claims on immune function which were based on the 
essentiality of nutrients (for vitamin D and zinc), claims on bowel function/maintenance of normal 
defecation (for sugar beet fibre, chicory inulin and hydroxyanthracene derivatives) and one claims on 
the absorption of micronutrients (for vitamin C). 
2. Objectives and scope 
This guidance is intended to assist applicants in preparing applications for the authorisation of health 
claims related to the immune system, the GI tract and defence against pathogenic microorganisms. It 
takes into account the outcomes of public consultations (i.e. on ‘a discussion paper’ (EFSA NDA Panel, 
2015a) and on the draft ‘guidance on the scientific requirements for health claims related to the 
gastro-intestinal tract, the immune system, and defence against pathogenic microorganisms’). The 
guidance document has been restructured to avoid overlapping with the general scientific guidance 
for stakeholders on health claim applications, which addresses general issues that are common to all 
health claims and has been updated. 
Examples of claims evaluated by the Panel with a favourable opinion will be used to provide guidance 
to applicants on the scientific requirements for the substantiation of health claims in specific areas, 
whereas examples of claims evaluated by the Panel with an unfavourable opinion will be used to 
illustrate the shortcomings that prevented the substantiation of these claims. The Panel cannot, 
however, provide guidance to applicants on the scientific requirements for the substantiation of health 
claims (e.g. type and amount of studies needed for substantiation) in specific areas where no 
examples of favourable evaluations are available (i.e. claims on GI discomfort, on defence against 
pathogens, on beneficial changes in response to allergens, on the reduction or beneficial alteration of 
a risk factor for infections in the context of disease risk reduction claims, on claims related to 
functions of the immune system which are not based on the essentiality of nutrients). 
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Issues related to the scientific substantiation that are common to all health claims are addressed in 
the general scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016) 
and will not be reiterated in this document. This guidance does not intend to provide an exhaustive 
list of beneficial physiological effects and of studies/outcome variables which could be acceptable for 
claims substantiation, or address potential health relationships and related outcome measures which 
have not been considered by the Panel yet in the context of a particular application. The guidance will 
be kept under review and will be amended and updated in the light of experiences gained from the 
evaluation of additional health claim applications in this area. 
This guidance supersedes the guidance on the scientific requirements for health claims related to gut 
and immune function published in 2011 and should be read in conjunction with the General scientific 
guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016), the Scientific and 
technical guidance for the preparation and presentation of an application for authorisation of a health 
claim (EFSA NDA Panel, 2011c), Regulation on Nutrition and Health Claims made on foods, 3 the 
Guidance on the implementation of Regulation (EC) No 1924/2006 (Standing Committee on the Food 
Chain and Animal Health, 2007), Commission Regulation (EC) No 353/2008, 4  the Commission 
Implementing Decision of 24 January 2013,5 and future guidelines and regulations, as applicable.   
3. Function claims 
3.1. Claims on the functions of the immune system  
3.1.1. Claims based on the essentiality of nutrients 
Claims on the maintenance of (unspecified) functions of the immune system which were based on the 
essentiality of nutrients (e.g. vitamins C (EFSA NDA Panel, 2009b), D (EFSA NDA Panel, 2010d), A 
(EFSA NDA Panel, 2009a), B12 (EFSA NDA Panel, 2009d), B6 (EFSA NDA Panel, 2009e), zinc (EFSA 
NDA Panel, 2009f), copper (EFSA NDA Panel, 2009g), folate (EFSA NDA Panel, 2009h), iron (EFSA 
NDA Panel, 2009i), selenium (EFSA NDA Panel, 2009c)) were evaluated by the NDA Panel with a 
favourable opinion.  
The scientific substantiation of claims on the maintenance of (unspecified) functions of the immune 
system was based on the essentiality of these nutrients, i.e. on the well-established biochemical role 
of such nutrients, and/or on deficiency symptoms involving the immune system. The use of 
unspecified functions of the immune system to substantiate such claims is because symptoms of 
deficiency of a nutrient can result from effects on multiple physiological functions, and it is sometimes 
not possible or appropriate to single out a precise function that is affected by deficiency of that 
nutrient in a particular organ or system. For these claims, the NDA Panel did not review the primary 
scientific studies submitted and it did not weigh the evidence.  
3.1.2. Claims other than those based on the essentiality of nutrients 
Claims proposed for nutrients which do not fulfil the concept of essentiality (e.g. vitamin C and 
function of the immune system in subjects performing intense physical activity was assessed in terms 
of duration and severity of common cold symptoms during and after extreme physical exercise (EFSA 
NDA Panel, 2009b)) are evaluated by the NDA Panel following the same general principles applied to 
other claims.  
Claims on the improvement or maintenance of unspecified functions of the immune system which are 
not based on the essentiality of nutrients are not sufficiently defined for a scientific evaluation. The 
                                                          
3  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:EN:PDF 
4  Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation 
of health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council 
(Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2008R0353:20091221:EN:PDF    
5 Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of specific conditions for 
health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L 
22, 25.1.2013, p. 25–28. Available at http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D0063 
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specific function of the immune system and the appropriate outcome variables(s) which may be used 
for the scientific evaluation of the claimed effect in vivo in humans must be identified.  
In this context, outcome variable(s) which can be measured in vivo in humans by generally accepted 
methods but do not refer to a benefit on specific functions of the body cannot constitute the only 
basis for the scientific substantiation of a health claim. These include:  
i) changes in immune markers, e.g. numbers of various lymphoid subpopulations in the circulation, 
proliferative responses of lymphocytes, phagocytic activity of phagocytes, lytic activity of natural killer 
cells and cytolytic T cells, production of cellular mediators, serum and secretory immunoglobulin 
levels, delayed-type hypersensitivity responses; 
ii) changes in markers of inflammation (including markers of chronic, subclinical inflammation), such 
as interleukins or C-reactive protein; 
iii) changes in short-chain fatty acid production (including butyrate) in the gut;  
iv) changes in the structure of the intestinal epithelium; 
v) changes in the composition of the gut microbiota.  
Changes in these outcome variable(s) should be accompanied by evidence of a beneficial physiological 
effect or clinical outcome in the application. Alternatively, changes in some of these outcome variables 
could be proposed as part of the mechanism(s) by which a food may exert the claimed effect, i.e. 
induce a beneficial change on a specific function of the body.  
3.2. Claims on gastrointestinal discomfort  
Occasional episodes of abdominal pain or discomfort (e.g. bloating, abdominal pain/cramps, straining 
and borborygmi (rumbling)), in the absence of organic diseases or biochemical abnormalities, are 
commonly associated with food or drug intake or with alterations of bowel habits and vary between 
individuals in frequency and severity.  
Claims on the reduction of GI discomfort have been proposed. Symptoms such as abdominal pain, 
cramps, bloating, straining, borborygmi (rumbling) and sensation of incomplete evacuation are 
associated with GI discomfort. Reducing GI discomfort is considered an indicator of improved GI 
function, which is a beneficial physiological effect for the general population. 
3.2.1. Claims on gastrointestinal discomfort for the general population 
GI discomfort may be measured by using validated subjective global symptom questionnaires, as 
described in consensus opinions (Veldhuyzen van Zanten et al., 1999; Irvine et al., 2006), and in an 
EFSA opinion (EFSA NDA Panel, 2014a). Changes in one or more of the individual symptoms (e.g. 
representing different domains of the questionnaire), as well as changes in defecation habits (e.g. 
outcome variable(s) related to the maintenance of normal defecation), may be used as supportive 
evidence for the mechanisms by which the food/constituent could exert the claimed effect, but cannot 
be used alone for the substantiation of a claim on the reduction of GI discomfort. Validated ‘quality of 
life questionnaires’ may also provide supportive evidence for claims on GI discomfort (EFSA NDA 
Panel, 2016).6  
All claims on the reduction of GI discomfort for the general population were evaluated by the Panel 
with an unfavourable opinion (for example EFSA (2008) and EFSA NDA Panel (2012d, 2013d, 2014a, 
2014d)). Lack of validation of the measurement scales/questionnaires used to assess the claimed 
effect (EFSA NDA Panel, 2014d), lack of assessment of the subjective global symptoms (a combined 
measure of efficacy which would indicate adequate relief of symptoms of GI discomfort) but rather of 
the individual symptoms (EFSA NDA Panel, 2014a), and the short duration of the human intervention 
studies provided (EFSA NDA Panel, 2011i) were some of the reasons preventing a favourable opinion. 
Owing to the fluctuating nature of GI symptoms, evidence for a sustained effect with continuous 
                                                          
6 General considerations on the validation of questionnaires for self-reported outcomes and their use as outcome variables for 
the scientific substantiation of health claims are given in section 7.4 and Annex C of the general scientific guidance for 
stakeholders for health claim applications. Available at http://www.efsa.europa.eu/en/efsajournal/pub/4367   
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consumption of the food/constituent over extended periods of time (e.g. 4–8 weeks) should be 
provided (Irvine et al., 2006). 
With respect to the study group, irritable bowel syndrome (IBS) is a functional GI disorder 
characterised by chronic or recurrent abdominal pain or discomfort, mostly associated with defecation 
abnormalities (consistency of stools and frequency of defecations) in the absence of a detectable 
organic or pathological cause. Episodes of abdominal pain or discomfort occur both in healthy people 
and in individuals suffering from IBS, and the difference between the two is the higher frequency 
and/or greater severity of the symptoms in IBS patients. IBS patients or subgroups of IBS patients 
(Rome III criteria) are generally considered a suitable study group to substantiate claims on GI 
discomfort intended for the general population. 
3.2.2. Claims on gastrointestinal discomfort for infants 
Reduction of GI discomfort is a beneficial physiological effect for infants and young children. 
Unexplained bouts of crying in infants have been traditionally attributed to GI disturbances and pain 
(Shamir et al., 2013). The term infant colic is commonly used to reflect this situation in infants. Infant 
colic has been included in the list of childhood functional GI disorders of the Rome III Coordinating 
Committee, with diagnostic criteria based on infant crying time and frequency, after excluding other 
reasons for crying (Hyman et al., 2006). Crying time can be used to assess GI discomfort in infants 
diagnosed with infant colic.  
In principle, owing to the variability and fluctuating nature of infant colic, its diagnosis relies on the 
duration of symptoms for at least 1 week according to the Rome III criteria, and for the same reason, 
evidence for an effect of the food/constituent on infant’s colic could be provided by studies of similar 
duration. Similarly, owing to the interindividual variability and fluctuating nature of infant colic, 
asymptomatic infants should be included in these studies, both in the treatment and control groups. 
Two claims on the reduction of GI discomfort targeting infants and young children (EFSA NDA Panel, 
2014b, 2015c) were evaluated by the Panel with an unfavourable opinion.  
3.2.3. Claims on the reduction of excessive intestinal gas accumulation  
A claim on activated charcoal and reduction of excessive intestinal gas accumulation, which can be 
measured in vivo in humans by generally accepted methods, was evaluated by the NDA panel with a 
favourable opinion (EFSA NDA Panel, 2011j). Although the reduction of intestinal gas accumulation 
per se does not refer to a benefit on a function of the body directly, the Panel considered that the 
reduction of excessive intestinal gas accumulation generally7 leads to a reduction in GI discomfort, 
which is a beneficial physiological effect for the general population.  
Appropriate outcome variables include, for example, breath hydrogen levels measured by hydrogen 
breath test, and intestinal gas volume assessed by imaging techniques (e.g. functional magnetic 
resonance imaging).  
The claim on activated charcoal and reduction of excessive intestinal gas accumulation was based 
particularly on human intervention studies which consistently showed an effect of the food/constituent 
on decreasing the amount of intestinal gas accumulation and on a known mechanism of action. Single 
meal studies were sufficient in this case for the scientific substantiation of the claim because activated 
charcoal is expected to induce the claimed effect within hours of consumption and adaptation to the 
effect of charcoal upon repeated consumption through compensatory mechanisms is unlikely.  
3.3. Claims on maintenance of normal defecation 
Normal bowel habits vary considerably from person to person with regard to the frequency of bowel 
movements (i.e. number of defecations per interval of time), the consistency of stools and faecal bulk.  
                                                          
7  In most, but not all subjects. 
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Functional constipation is a disorder characterised by the absence of a detectable organic or 
pathological cause for which diagnostic criteria have been established. 8  Subjects in the general 
population may, however, experience one or more symptoms of functional constipation without 
meeting the diagnostic criteria for the disorder (e.g. low frequency of defecations, lumpy or harder 
stools, sensation of incomplete evacuation).  
Claims on the maintenance of normal defecation (a bowel function) have been proposed only in the 
context of facilitating defecation (e.g. by one or more of the following means: increasing the 
frequency of bowel movements, increasing faecal bulk, decreasing the consistency of stools, 
decreasing transit time) in subjects with one or more signs/symptoms of functional constipation. In 
this context, maintenance of normal defecation is considered a beneficial physiological effect for the 
general population provided that it does not result in diarrhoea. 
Several claims on the maintenance of normal defecation were evaluated by the Panel with a 
favourable opinion (e.g. for dried prunes (EFSA NDA Panel, 2012c), lactulose (EFSA NDA Panel, 
2010b), wheat bran fibre (EFSA NDA Panel, 2010f), rye fibre (EFSA NDA Panel, 2011k), oat and barley 
grain fibre (EFSA NDA Panel, 2011l), chicory inulin (EFSA NDA Panel, 2015b), hydroxyanthracene 
derivatives (EFSA NDA Panel, 2013c), lactitol (EFSA NDA Panel, 2015d)). The scientific substantiation 
of these claims was based on human intervention studies showing an effect of the food/constituent on 
different outcomes which, in the context of the known mechanism(s) by which the food/constituent 
could exert the claimed effect, contributed to the maintenance of normal defecation. For example, 
changes in transit time may or may not contribute to the maintenance of normal defecation. However, 
a claim on lactulose and a reduction in transit time was evaluated by the Panel with a favourable 
opinion because, in the context of the human intervention studies provided and of the mechanisms of 
action, it is well established that lactulose contributes to normal defecation by increasing the stool 
water content and softening the stools via increasing the osmotic pressure and slightly acidifying the 
colonic content. Similarly, faecal bulk is not among the signs/symptoms in the definition of functional 
constipation. However, claims on dietary fibre (wheat bran fibre, oat and barley grain fibre) and an 
increase in faecal bulk have been evaluated by the Panel with favourable opinions because in the 
context of the human intervention studies provided and of the mechanism of action, it is well 
established that cereal grain fibre contributes to the maintenance of normal defecation and dietary 
reference values for dietary fibre in mixed diets have been established on the basis of maintaining 
normal bowel function in relation to normal defecation.  
Based on the experience gained during the scientific evaluation of these claims, the Panel considers 
that maintenance of normal defecation may be assessed by a number of outcome variables which 
could provide information about the function and eventually about the underlying mechanism of 
action, some of which may be interrelated (e.g. stool frequency, stool consistency, sensation of 
complete/incomplete evacuation, faecal bulk, transit time). The Panel will consider the information 
provided on these variables to evaluate the claim.  
Frequency of defecations, stool consistency (e.g. by using the Bristol Stool Form Scale), sensation of 
complete/incomplete evacuation and faecal bulk can be assessed directly by the investigators or by 
using validated questionnaires for self-reported outcomes.9 Changes in transit time may be measured, 
e.g. by using radiopaque markers.  
The study duration will depend on the food/constituent and its characteristics. In principle, the 
duration should be adequate in order to exclude adaptation to the continuous consumption of the 
food/constituent through compensatory mechanisms and chance findings for fluctuating outcome 
measures (e.g. 4–8 weeks).  
                                                          
8  Diagnostic criteria which must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
(Rome III):  
1. Must include two or more of the following: a. Straining during at least 25% of defecations; b. Lumpy or hard stools in at 
least 25% of defecations; c. Sensation of incomplete evacuation for at least 25% of defecations; d. Sensation of anorectal 
obstruction/blockage for at least 25% of defecations; e. Manual manoeuvres to facilitate at least 25% of defecations (e.g. 
digital; evacuation, support of the pelvic floor); f. Fewer than three defecations per week; 
2. Loose stools are rarely present without the use of laxatives; 
3. Insufficient criteria for irritable bowel syndrome. 
9 General considerations on the validation of questionnaires for self-reported outcomes and their use as outcome variables for 
the scientific substantiation of health claims are given in Section 7.4 and Annex C of the general scientific guidance for 
stakeholders for health claim applications. Available at http://www.efsa.europa.eu/en/efsajournal/pub/4367 
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With respect to the study group, results from studies conducted in individuals with functional (chronic) 
constipation, including subjects with IBS, could be used for the scientific substantiation of these claims 
for the general population. However, the rationale for extrapolation of results obtained in subjects 
with chronic constipation under pharmacological treatment to the target population for the claim 
should be provided, and will be considered on a case-by-case basis (e.g. evidence for a lack of 
interaction between the food and the medications used on the claimed effect). 
3.4. Claims on digestion and/or absorption of nutrients 
3.4.1. Claims on digestion and/or absorption of macronutrients 
Whether improved digestion of macronutrients is considered a beneficial physiological effect may 
depend on the consequences of reduced digestion of that nutrient (e.g. the effect of undigested 
nutrient in the GI tract).  
Claims related to the reduced absorption of macronutrients, such as glucose or cholesterol, are 
considered in the context of reduced blood concentrations of these nutrients (EFSA NDA Panel, 
2011m, 2012a). 
Claims on improved lactose digestion 
Lactose maldigestion results from a reduced enzymatic capacity to digest lactose. Individuals with 
lactose maldigestion may display symptoms after lactose consumption such as nausea, diarrhoea and 
GI discomfort (e.g. cramping, bloating and flatulence). Improved lactose digestion may alleviate 
lactose maldigestion symptoms, and is considered a beneficial physiological effect for individuals with 
symptoms of lactose maldigestion.  
Two claims related to the effect of food/constituents (live yoghurt cultures (EFSA NDA Panel, 2010c) 
and lactase (EFSA NDA Panel, 2009k)) which are able to break down lactose and which therefore 
facilitate lactose digestion when consumed with lactose-containing foods have been evaluated by the 
Panel with favourable opinions. The scientific substantiation of these claims was based on human 
intervention studies showing an effect of the food/constituent on symptoms of lactose maldigestion 
(subjective outcomes), as well as an increase in lactose digestion (objectively measured by the breath 
hydrogen concentration method) when consumed with lactose-containing foods by subjects with 
symptoms of lactose maldigestion, and also on the biological plausibility of the effect.  
The characterisation of the study population (i.e. subjects with symptoms of lactose maldigestion, 
irrespective of the cause), in the studies submitted for the substantiation of these claims is particularly 
important. Subjects with symptoms of lactose maldigestion could be identified through the 
appearance of symptoms upon lactose consumption and which respond to lactose withdrawal.  
Individuals with lactose maldigestion (i.e. with difficulties in digesting lactose) have been considered 
by risk managers as an acceptable target population for health claims made on foods.  
3.4.2. Claims on digestion/absorption/utilisation of micronutrients 
Claims related to absorption of micronutrients (vitamin C (EFSA NDA Panel, 2009b), meat and fish 
(EFSA NDA Panel, 2011n) and improvement of non-haem iron absorption; vitamin D and absorption 
and utilisation of calcium and phosphorus (EFSA NDA Panel, 2009j); fats and normal absorption of fat-
soluble vitamins (EFSA NDA Panel, 2011o)) have been evaluated by the Panel with favourable 
opinions. The claimed effect (improved absorption of the above-mentioned nutrients) was considered 
by the Panel as a beneficial physiological effect because absorption was a limiting factor for the 
maintenance of an adequate status of the nutrient, and because the absorbed nutrient could be 
utilised by the body.  
For example, iron deficiency is one of the most common micronutrient deficiencies in the European 
Union (EU), and can result in anaemia. Non-haem iron is generally not well absorbed in the human 
intestine, and can be a limiting factor for the maintenance of adequate iron status. An increase in iron 
absorption leading to an increase in iron retention is therefore a beneficial physiological effect for the 
general population.  
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Similarly, inadequate dietary calcium intake, low calcium absorption and low calcium retention may 
contribute to impaired bone development in early life. Calcium absorption can be a limiting factor to 
achieve the target retention rate for calcium in preterm infants, in healthy term infants, and in infants 
with disturbances of lipid digestion which can result in insufficient calcium in the body to meet the 
demands of growing bone. An increase in calcium absorption leading to an increase in calcium 
retention is, therefore, a beneficial physiological effect for infants (EFSA NDA Panel, 2011p).  
3.5. Claims on (immune) defence against pathogens 
3.5.1. General considerations  
Defence against pathogens comprises different mechanisms, which act in concert to protect against 
infection. The presence of pathogenic microorganisms may cause clinical infections at various sites of 
the body, and defence against pathogens at a specific site of the body is considered a beneficial 
physiological effect for the general population. For function claims on defence against pathogens, the 
claim should specify the site of infection (e.g. defence against pathogens in the GI tract, in the upper 
respiratory tract or in the urinary tract), the type of pathogenic microorganism (e.g. bacteria, virus, 
fungi, any microorganism) and the target population.  
The scientific evidence for the substantiation of health claims related to defence against pathogens 
can be obtained from human intervention studies showing an effect on clinical outcomes related to 
infections (e.g. incidence, severity and/or duration of symptoms). The infectious nature of the disease 
should be established, e.g. by clinical differential diagnosis alone or in combination with 
microbiological data and/or the use of validated questionnaires,10 depending on the study context and 
type of infection.  
Vaccination confers immunity to certain infectious diseases. Even if a strict correlation between 
antibody titres in response to vaccination and protection against infection is not always evident, cut-
off values of antibody titres in response to vaccination indicating protection have been established for 
many vaccines. An increase in the number of responders to vaccination (i.e. attaining antibody titres 
beyond a cut-off value which is considered to protect against the infection) is an appropriate outcome 
variable for the scientific substantiation of claims related to immune defence against pathogens.   
The (transient) presence of microorganisms and/or their toxins at a particular body site may not 
reflect a clinical infection. However, if evidence is provided that the presence of a particular 
microorganism (and/or their toxins) at a particular body site, or the presence of a certain amount of 
the microorganism, would eventually lead to a clinical infection in the target population (general 
population or subgroups thereof), for which the claim is made, microbiological data could be used 
instead of (i.e. replace) clinical outcomes related to infections (e.g. incidence, severity and/or duration 
of symptoms). The evidence provided will be evaluated by the NDA Panel on a case-by-case basis.  
Other outcome variables, such as changes in relevant immunological markers, may provide supportive 
evidence on the mechanism (e.g. through the activation of the immune system) by which the 
food/constituent could exert the claimed effect, but alone are not appropriate outcome variables for 
the substantiation of claims related to immune defence against pathogens.  
All claims related to (immune) defence against pathogens at different body sites have been evaluated 
by the Panel with unfavourable opinions. A main weakness of the majority of the human intervention 
studies provided for the substantiation of these claims was the lack of appropriate clinical outcomes 
related to infections (e.g. incidence, severity and/or duration of symptoms) and uncertainties 
regarding the infectious nature of the disease.  
With respect to the study group, subjects without an infection at baseline, including subjects at high 
risk for infection without an infection at baseline (e.g. travellers to high risk countries, subjects under 
intense physical exercise, elderly individuals in nursing homes, children attending day-care centres, 
subjects challenged with live viruses/bacteria) could be suitable study groups for the scientific 
substantiation of claims on (immune) defence against pathogens for the general population, as long 
                                                          
10 General considerations on the validation of questionnaires for self-reported outcomes and their use as outcome variables for 
the scientific substantiation of health claims are given in Section 7.4 and Annex C of the general scientific guidance for 
stakeholders for health claim applications. Available at http://www.efsa.europa.eu/en/efsajournal/pub/4367  
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as the methods and the inclusion/exclusion criteria used to characterise the study group in relation to 
the absence of ongoing infectious diseases at baseline are clearly defined. 
In general, results obtained in adults cannot be used for the scientific substantiation of health claims 
involving the GI tract and/or the immune system, including claims related to (immune) defence 
against pathogens, for which the target population is infants and young children, and vice versa. If 
the target group is wider or different from the study group, evidence or a rationale for extrapolation 
of the results from the study group to the target population should be provided and will be considered 
by the Panel on a case-by-case basis. 
3.5.2. Claims on (immune) defence against pathogens in the gastrointestinal 
tract 
The scientific evidence for the substantiation of health claims related to defence against pathogens in 
the GI tract can be obtained from human intervention studies showing an effect on clinical outcomes 
related to GI infections, for example incidence, severity and/or duration of diarrhoeal episodes. The 
infectious aetiology of diarrhoeal episodes, however, should be ascertained. In this context, GI 
infection clinically diagnosed by the primary care or hospital physician following well defined criteria 
can be used as an appropriate outcome variable for the scientific substantiation of the claim, provided 
that adequate exclusion criteria for the most common non-infectious causes of diarrhoea have been 
applied (EFSA NDA Panel, 2011a). Microbiological data could also be used to ascertain the infectious 
aetiology of diarrhoeal episodes.  
3.5.3. Claims on (immune) defence against pathogens in the respiratory tract  
The scientific evidence for the substantiation of health claims related to defence against pathogens in 
the respiratory tract can be obtained from human intervention studies showing an effect on clinical 
outcomes related to respiratory infections (e.g. incidence, severity and/or duration of symptoms), 
either of the upper respiratory tract (such us rhinitis, pharyngitis, sinusitis, otitis media and common 
cold), of the lower respiratory tract (such as pneumonia, bronchitis and bronchiolitis), or both. For 
instance, upper or lower respiratory tract infections clinically diagnosed by the primary care or hospital 
physician following well defined criteria can be used as an appropriate outcome variable for the 
scientific substantiation of the claim, provided that adequate exclusion criteria for the most common 
non-infectious causes (e.g. allergic diseases) of the signs and symptoms used for diagnosis of the 
respiratory infection have been applied (i.e. differential diagnosis). Microbiological data could also be 
used to ascertain the infectious aetiology of clinically diagnosed episodes.  
A main weakness of the human intervention studies submitted for the substantiation of claims on 
defence against pathogens in the upper respiratory tract (e.g. EFSA NDA Panel (2010e, 2012b, 2013a, 
2015e)) was the use of non-validated questionnaires on self-reported symptoms in order to assess the 
incidence/severity/duration of common cold episodes.    
3.5.4. Claims on defence against pathogens in the lower urinary tract  
Presence of bacteria in the urinary tract may cause symptomatic urinary tract infections (UTIs). UTI is 
the most common infection in girls and women, with the incidence rising with age and sexual activity. 
Symptomatic UTIs are usually accompanied by bacteriuria at levels of ≥ 105/mL of midstream urine, 
and it has been estimated that uropathogenic strains of Escherichia coli are the most common cause 
of UTIs (Ronald, 2003). Defence against bacterial pathogens in the lower urinary tract is considered a 
beneficial physiological effect for the general population and subgroups thereof (e.g. postmenopausal 
women), for example EFSA NDA Panel (2011b, 2014c). 
The scientific evidence for the substantiation of function claims related to defence against pathogens 
in the lower urinary tract can be obtained from human intervention studies showing an effect on 
clinical outcomes related to UTIs (e.g. incidence, severity and/or duration of symptoms). 
Microbiological data could be used instead of (i.e. replace) clinical outcomes related to infections 
under the conditions referred to in Section 3.5.1. 
Bacterial adherence to mucosal surfaces is generally considered an important prerequisite for 
colonisation and infection with bacteriuria (Harber and Asscher, 1985). However, in vitro inhibition of 
the bacterial adhesion to uroepithelial cells, which has been proposed for the scientific substantiation 
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of these claims, is not a direct measure of defence against pathogens in the lower urinary tract and 
does not predict the occurrence of a clinically relevant inhibition of the bacterial adhesion to 
uroepithelial cells in vivo in humans (EFSA NDA Panel, 2013b). In vitro inhibition of the bacterial 
adhesion to uroepithelial cells could, therefore, provide evidence on the mechanism by which a 
food/constituent could exert the claimed effect, but alone it is not an appropriate outcome variable for 
the substantiation of the claim. 
With respect to the study population, subjects without infections of the urinary tract at baseline, but at 
high risk of infections (e.g. women with past uncomplicated, sporadic or recurrent cystitis), are 
considered suitable study groups to substantiate claims on defence against bacterial pathogens in the 
lower urinary tract for the general population. Where appropriate, the confounding role of medication 
should be considered.  
3.5.5. Claims on defence against vaginal pathogens 
Bacterial pathogens (e.g. Gardnerella vaginalis) are the most common cause of vaginal infections. 
Unlike any other anatomical site of the body, most vaginal vaults are dominated by one or more 
species of Lactobacillus. In over 70% of women, vaginal microbiota is dominated by lactobacilli 
(> 50%). The diagnosis of bacterial vaginosis is currently based on the Nugent score. 11  Other 
pathogenic microorganisms also cause vaginal infections e.g. yeasts, such as Candida albicans, and 
parasites, such as Trichomonas vaginalis. 
Defence against vaginal pathogens is a beneficial physiological effect for the general female 
population. The claimed effect can be achieved by increasing the proportion of lactobacilli and/or 
decreasing the proportion of potentially pathogenic bacteria and/or yeasts in the vagina, as assessed, 
for example by beneficial changes in Nugent scores (EFSA NDA Panel, 2011d) and/or by inducing 
beneficial changes in clinical outcomes related to vaginal infections (e.g. incidence, severity and/or 
duration of symptoms) upon oral consumption of the food/constituent. The intravaginal route of 
administration does not provide pertinent data for health claims on food. 
With respect to the study group, women without vaginosis at baseline, but at high risk of infections 
(e.g. women with past uncomplicated, sporadic or recurrent vaginosis), are considered suitable study 
groups to substantiate claims on defence against vaginal pathogens for the general population. Where 
appropriate, the confounding role of medication should be considered. 
3.6. Claims on a beneficial change in response to allergens  
The general healthy population comprises persons with an increased risk of developing allergic 
(atopic) reactions, such as allergic rhinitis, allergic asthma, atopic dermatitis and food allergy. Allergic 
manifestations, such as asthma, urticaria, eczema and GI manifestations, are caused by undesirable 
immune responses to environmental allergens, including food allergens. Beneficial changes in 
response to allergens may comprise different mechanisms, which act in concert to reduce allergic 
reactions. A beneficial change in response to allergens is a beneficial physiological effect for subjects 
at risk of allergic reactions.  
In principle, the scientific evidence for the substantiation of function claims related to a beneficial 
change in response to allergens can be obtained from human studies showing a decreased incidence, 
severity and/or duration of allergic manifestations in subjects at risk of allergic reactions but free of 
symptoms at baseline. Allergic symptoms are not always easy to distinguish from non-allergic 
phenomena, and data from self-reported allergies are usually unreliable and insufficient for a 
diagnosis of allergy. In addition, differences in exposure to the triggering allergen(s) in the 
intervention and control groups should be carefully considered.  
It should be noted that an effect of a food/constituent on the risk of one clinical type of allergy (e.g. 
respiratory) does not necessarily predict an effect of the same food/constituent on the risk of another 
                                                          
11 Nugent scores are classified into normal (0–3, lactobacilli are present, but not Gardnerella/Bacteroides or curved Gram-
negative bacilli), intermediate (4–6, colonisation by Bacteroides/Gardenella and curved Gram-variable rods (Mobiluncus)), and 
BV (7–10, BV with domination of Gardnerella/Bacteroides or curved Gram-negative bacilli and absence of lactobacilli) 
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type of allergy (e.g. food allergy). The type of allergy that is the subject of the claim should be 
specified. 
Other outcome variables, such as basophil activation test, tryptase in plasma and allergen specific 
immunoglobulin E (IgE), may provide supportive evidence on the (e.g. immune) mechanisms and 
biological plausibility of a claim related to a beneficial change in response to allergens, but they 
cannot be used alone for the substantiation of these claims.  
A claim related to normal resistance to cedar pollen allergens has been evaluated by the Panel with an 
unfavourable opinion (EFSA NDA Panel, 2011f). 
4. Disease risk reduction claims 
4.1. Claims on the reduction (or beneficial alteration) of a risk factor for 
infections 
All the disease risk reduction claims related to the reduction (or beneficial alteration) of a risk factor 
for infections have been evaluated by the NDA Panel with unfavourable opinions (e.g. increasing 
secretory immunoglobulin A (IgA) in the context of reducing the risk of common cold with sore throat 
(EFSA NDA Panel, 2011g, 2011h); reducing the risk of Clostridium difficile diarrhoea by reducing the 
presence of C. difficile toxins (EFSA NDA Panel, 2010a); reducing the risk of urinary tract infections by 
inhibiting the adhesion of certain bacteria to the urinary tract (EFSA, 2009b; EFSA NDA Panel, 2009l, 
2014e); a decrease in bacterial, viral and parasitic enteric pathogens in the context of reducing the 
risk of travellers’ diarrhoea (EFSA, 2009a)).  
The presence of certain microorganisms (or an increase in the number of certain microorganisms) or 
their toxins at particular sites of the body has been independently associated with an increased risk of 
infections, and there is evidence for the biological basis through which the risk factor can contribute to 
the development of infections. For example, the presence of toxigenic C. difficile in the GI tract may 
be associated with the incidence of acute diarrhoea, and reducing the risk of C. difficile diarrhoea by 
reducing the presence of C. difficile toxins is a beneficial physiological effect in the context of disease 
risk reduction claims. In this case, evidence that the dietary intervention with the specific 
food/constituent induces a reduction (or beneficial alteration) of the risk factor (e.g. toxigenic 
C. difficile or C. difficile toxins) would be sufficient for the scientific substantiation of the claim. 
Evidence for an effect on clinical outcomes related to infections (e.g. incidence, severity and/or 
duration of symptoms) is not required. 
For less well-established risk factors (e.g. reduced concentrations of secretory IgA as a risk factor for 
influenza or common cold, in vitro bacterial adhesion as a risk factor for lower urinary tract infections), 
evidence that the dietary intervention with the specific food/constituent induces a reduction (or 
beneficial alteration) of the risk factor and also a reduction of the risk of disease needs to be provided. 
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GI gastrointestinal 
IBS irritable bowel syndrome 
ID identification number 
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